Kaya Holdings Boosts Operations In Greece With 50% Acquisition Of Epidaurus Medical Cannabis Project

Cannabis company Kaya Holdings, Inc. KAYS announced Tuesday that its majority-owned subsidiary Kaya Farms Greece has entered into an agreement to acquire 50% of a medical cannabis project in Epidaurus, Greece.

The move marks the company's second cannabis venture in the EU nation. Terms of the deal were not disclosed.

What It Means For Kaya?

The Epidaurus site consists of two connected industrial buildings, comprising roughly 50,000 square feet under open-air space on 2.8 acres of land. The site has its own independent industrial electrical power center and ample water supply to service the facility's needs.

The Greek Kaya Project will include 25,000 square feet of indoor cannabis cultivation, a 15,000 square foot EU-GMP extraction and processing facility and a 10,000 square-foot EU-GMP packing area.

In addition, there's plenty of room for expansion to construct an additional 15,000 square feet on the site. 

The new project joins the company's 15-acre project in Thebes, Greece, allowing KAYS to fast-track the cultivation and processing of its proprietary branded cannabis products for distribution in legal EU markets.

A year ago, Kaya bought a 50% interest in Athens-based Greekkannabis SA, which holds a license to build a facility that would cover some 225,000 square feet of cannabis cultivation and 80,000 square feet of cannabis processing on a 15-acre property in Thebes.

What's Next?

The Fort Lauderdale, Florida company, said that plans to cultivate and manufacture KAYS proprietary cannabis brands (CBD/THC) for distribution in the Greek, German and other EU markets as permitted by local regulations once the joint venture gets financing and receives all regulatory approvals.

"We expect that 2022 will be a breakthrough year for us as our efforts to gain a foothold in the European cannabis market begin to come to fruition," Kaya's CEO Craig Frank said. "We have strengthened our international ties substantially in 2021 and now have the network to undertake bold steps to claim our stake in a global cannabis sector still in its infancy."

KAYA'S Price Action

Kaya's shares traded at $0.1326 per share at the time of this writing Tuesday afternoon.

Photo: Courtesy of Johnny Chen on Unsplash

Posted In: Craig FrankGreecemedical marijuanaCannabisM&ANewsPenny StocksEurozoneMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.